Inactive Instrument

Ortho Clinical Diagnostics Holdings plc

Equities

OCDX

GB00BMDNH979

Medical Equipment, Supplies & Distribution

Ortho Clinical Diagnostics Holdings plc Revises Earnings Guidance for the Year 2021

August 04, 2021 at 04:05 pm EDT

Ortho Clinical Diagnostics Holdings plc revised earnings guidance for the year 2021. For the year, the company now expects Core Revenue to be $1.95 billion - $1.98 billion against previous guidance of $1.93 billion - $1.96 billion.

Latest news about Ortho Clinical Diagnostics Holdings plc

Ortho Clinical Diagnostics Holdings plc(NasdaqGS:OCDX) dropped from S&P Global BMI Index	22-06-01	CI
Ortho Clinical Diagnostics Holdings plc(NasdaqGS:OCDX) dropped from S&P Healthcare Equipment Select Industry Index	22-06-01	CI
Ortho Clinical Diagnostics Holdings plc(NasdaqGS:OCDX) dropped from S&P TMI Index	22-06-01	CI
Ortho Clinical Diagnostics Holdings plc Terminates Credit Agreement	22-05-27	CI
Quidel Corporation completed the acquisition of Ortho Clinical Diagnostics Holdings plc.	22-05-26	CI
Quidel, Ortho Clinical Expect Pending Transaction to Close on Friday	22-05-26	MT
Ortho Clinical Diagnostics Holdings plc(NasdaqGS:OCDX) dropped from NASDAQ Composite Index	22-05-26	CI
Quidel's Shareholders Approve Ortho Clinical Diagnostics Holdings Acquisition Deal	22-05-16	MT
Ortho Clinical Diagnostics Holdings plc Reports Earnings Results for the First Quarter Ended April 03, 2022	22-05-04	CI
Transcript : Ortho Clinical Diagnostics Holdings plc, Q1 2022 Earnings Call, May 04, 2022	22-05-04
Insider Sell: Ortho Clinical Diagnostics Holdings	22-04-06	MT
Morgan Stanley Downgrades Ortho Clinical Diagnostics to Equal Weight From Overweight, Lowers PT to $16.90 From $26	22-02-17	MT
Evercore ISI Upgrades Ortho Clinical Diagnostics Holdings to Outperform From In-Line; Price Target is $21	22-02-17	MT
Transcript : Ortho Clinical Diagnostics Holdings plc, Q4 2021 Earnings Call, Feb 16, 2022	22-02-16
Ortho Clinical Diagnostics Holdings plc Reports Earnings Results for the Full Year Ended January 02, 2022	22-02-16	CI
Ortho Clinical Diagnostics Holdings plc Reports Earnings Results for the Fourth Quarter Ended January 02, 2022	22-02-16	CI
Ortho Clinical Diagnostics Seeks UK Court Approval of Shareholder Vote on Acquisition by Quidel	22-01-24	MT
Transcript : Ortho Clinical Diagnostics Holdings plc Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 09:00 AM	22-01-11
Insider Sell: Ortho Clinical Diagnostics Holdings	22-01-07	MT
Insider Sell: Ortho Clinical Diagnostics Holdings	22-01-07	MT
Ortho Clinical Diagnostics Holdings Reports Preliminary Q4 Revenue Range in Line With Estimates	22-01-06	MT
Ortho Clinical Diagnostics Holdings plc Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Fiscal Year Ended January 2, 2022	22-01-06	CI
Ortho Clinical Diagnostics Holdings plc Provides Earnings Guidance for the Fourth Quarter Ended January 2, 2022	22-01-06	CI
HC Wainwright Downgrades Ortho Clinical Diagnostics to Neutral From Buy Amid Deal to Be Bought by Quidel	21-12-27	MT
Barclays Cuts Ortho Clinical Diagnostics Holdings to Equalweight From Overweight, Price Target to $25 From $29	21-12-27	MT

Chart Ortho Clinical Diagnostics Holdings plc

Duration

Period

Chart Ortho Clinical Diagnostics Holdings plc

More charts

Company Profile

Ortho Clinical Diagnostics Holdings PLC is an in vitro diagnostics (IVD) diagnostic company. The Company provides laboratory testing and blood-typing solutions to the clinical laboratory and transfusion medicine communities. The Company provides customized solutions for clinical outcomes, lab performance and staffing challenges. The Company operates through two lines of business such as Clinical Laboratories and Transfusion Medicine. Its Clinical Laboratories business focuses on clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across therapeutic areas. The Transfusion Medicine business is focused on immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions. Its Donor Screening business is focused on instruments and tests used for blood and plasma screening for infectious diseases for customers, which include some of the donor testing institutions.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOMÉRIEUX	+1.19%	12.66B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.03%	7.04B
DIASORIN S.P.A.	+1.69%	5.39B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.51%	4.45B
LANTHEUS HOLDINGS, INC.	+1.73%	4.32B
10X GENOMICS, INC.	-50.32%	3.31B
ANDON HEALTH CO., LTD.	+6.90%	2.6B
VITROLIFE AB	-17.15%	2.01B
MYRIAD GENETICS, INC.	-3.40%	1.67B

Diagnostic & Testing Substances